Skip to search
Skip to main content
Back to Search
Start Over
Increasing Infliximab Dose Based on Symptoms, Biomarkers, and Serum Drug Concentrations Does Not Increase Clinical, Endoscopic, and Corticosteroid-Free Remission in Patients With Active Luminal Crohn's Disease
Authors :
MS MDL 1 Infection & Immunity D'Haens, Geert Vermeire, Severine Lambrecht, Guy Baert, Filip Bossuyt, Peter Pariente, Benjamin Buisson, Anthony Bouhnik, Yoram Filippi, Jérôme vander Woude, Janneke Van Hootegem, Philippe Moreau, Jacques Louis, Edouard Franchimont, Denis De Vos, Martine Mana, Fazia Peyrin-Biroulet, Laurent Brixi, Hedia Allez, Matthieu Caenepeel, Philip Aubourg, Alexandre Oldenburg, Bas Pierik, Marieke Gils, Ann Chevret, Sylvie Laharie, David Détré, Patricia Bertin, Marie Jo Williams, Sabrina GETAID MS MDL 1 Infection & Immunity D'Haens, Geert Vermeire, Severine Lambrecht, Guy Baert, Filip Bossuyt, Peter Pariente, Benjamin Buisson, Anthony Bouhnik, Yoram Filippi, Jérôme vander Woude, Janneke Van Hootegem, Philippe Moreau, Jacques Louis, Edouard Franchimont, Denis De Vos, Martine Mana, Fazia Peyrin-Biroulet, Laurent Brixi, Hedia Allez, Matthieu Caenepeel, Philip Aubourg, Alexandre Oldenburg, Bas Pierik, Marieke Gils, Ann Chevret, Sylvie Laharie, David Détré, Patricia Bertin, Marie Jo Williams, Sabrina GETAID
Publication Year :
2018
Details
Database :
OAIster
Notes :
English
Publication Type :
Electronic Resource
Accession number :
edsoai.on1395291453
Document Type :
Electronic Resource